Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Better Bear Market Buy: Vertex Pharmaceuticals vs. Biogen Stock
06:00am, Sunday, 18'th Dec 2022
Both stocks are heading for double-digit gains this year.
Is Biogen (BIIB) Stock Undervalued Right Now?
11:17am, Thursday, 08'th Dec 2022
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Biogen (BIIB), Sage Finish Zuranolone NDA Filing for Depression
12:02pm, Wednesday, 07'th Dec 2022
Biogen (BIIB) and Sage Therapeutics (SAGE) NDA submission for zuranolone for treating MDD and PPD is based on data from two late-stage studies, LANDSCAPE and NEST.
Why 2023 Could Be a Big Year for Biogen
10:38am, Wednesday, 07'th Dec 2022
Investors will soon learn if the company's Alzheimer's treatment gets the green light.
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment
09:49pm, Tuesday, 06'th Dec 2022
Atai, Biogen, and Sage are working to develop new treatments for mental illness.
Biogen Inc. (BIIB) Biogen and Sage Zuranolone Webcast Transcript
11:40am, Tuesday, 06'th Dec 2022
Biogen Inc. (NASDAQ:BIIB ) Biogen and Sage Zuranolone Webcast December 6, 2022 8:00 AM ET Company Participants Helen Rubinstein – Director-Investor Relations-Sage Therapeutics Chris Benecchi – Chi
Biogen's (BIIB) ALS Drug Tofersen Filing Accepted in Europe
11:17am, Tuesday, 06'th Dec 2022
Biogen's (BIIB) tofersen, if approved, will be the first genetically-targeted treatment for SOD1-ALS in Europe.
Can These 2 Stocks Crush the Market Again in 2023?
09:37am, Sunday, 04'th Dec 2022
Both are riding the wave of major clinical wins
Is Biogen Stock a Buy Now?
08:30am, Sunday, 04'th Dec 2022
Its revenue now has a plausible path to doubling, but risks remain high.
Biogen Inc. (BIIB) 5th Annual Evercore ISI HealthCONx Conference 2022 - (Transcript)
09:28pm, Thursday, 01'st Dec 2022
Biogen Inc. (NASDAQ:BIIB ) 5th Annual Evercore ISI HealthCONx Conference Call December 1, 2022 10:30 AM ET Company Participants Mike McDonnell - Chief Financial Officer Priya Singhal - Head of Global
Experimental drug Lecanemab may be a landmark breakthrough in battle against Alzheimer's
01:44pm, Wednesday, 30'th Nov 2022
Yahoo Finance's Anjalee Khemlani discusses positive news around an Alzheimer's drug, plus reports that China is considering a fourth round of COVID vaccines.
5 things to know about the new Alzheimer's drug — including why it may be risky for people who take blood thinners
11:38am, Wednesday, 30'th Nov 2022
Shares of Eisai and Biogen did not move dramatically after the drug companies reported the full results of the clinical trial for their experimental Alzheimer's disease therapy, but the findings point
Biogen's (BIIB) Lecanemab Shows Benefit but With Side Effects
10:32am, Wednesday, 30'th Nov 2022
Detailed data from Biogen (BIIB) and Eisai's Clarity AD shows that treatment with lecanemab in the early stages of Alzheimer's disease reduces the rate of cognitive decline but is associated with adve
Why This New Alzheimer's Update Is Likely To Spark A Debate For Biogen Investors
10:14am, Wednesday, 30'th Nov 2022
Biogen stock surged Wednesday after partner Eisai unveiled Alzheimer's treatment test results that two doctors reportedly described as "magnificent." The post Why This New Alzheimer's Update Is Likely
BIIB Stock Alert: What the Latest Alzheimer's Drug Data Means for Biogen
10:00am, Wednesday, 30'th Nov 2022
Biogen (NASDAQ: BIIB ) stock is on the move Wednesday after the company provided the latest update on its Alzheimer's drug candidate. According to a press release from the biotechnology company, lecan
